Mesenchymal stromal cells in polytrauma: from immune dysregulation to therapeutic potential.
5 affiliations
- 1Department of Orthopedic Surgery, UC Davis Health, Sacramento, CA, United States.
- 2Department of Biomedical Engineering, University of California, Davis, Davis, CA, United States.
- 3Department of Biomaterials, Institute of Clinical Dentistry, University of Oslo, Oslo, Norway.
- 4Experimental Trauma Surgery, Justus-Liebig University Giessen, Giessen, Germany.
- 5School of Pharmacy, The University of Jordan, Amman, Jordan.
Abstract
Polytrauma, defined as life-threatening injuries to multiple organ systems with an Injury Severity Score greater than 16, presents significant challenges for fracture healing, with nonunion rates substantially higher than in isolated fractures. The systemic inflammatory response syndrome (SIRS) and subsequent immune dysregulation characteristic of polytrauma create a hostile microenvironment that impairs normal bone regeneration. Mesenchymal stromal cells (MSCs; also termed mesenchymal stem/stromal cells) play critical roles in fracture healing through immunomodulation, osteogenic differentiation, and promotion of angiogenesis. However, emerging evidence suggests that MSC-mediated processes may be compromised in polytrauma settings. Importantly, direct evidence for endogenous MSC dysfunction in human polytrauma remains limited: much of the current understanding is inferred from isolated-fracture models, in vitro inflammatory-stimulation studies, and animal polytrauma systems rather than from controlled human trauma data. This review examines the mechanisms by which polytrauma is associated with disruption of MSC function, including altered macrophage polarization, excessive neutrophil activation, reduced regulatory T cell populations, and complement-mediated MSC injury. We synthesize the current understanding of MSC immunomodulatory effects in normal fracture healing and contrast this with their dysfunction in polytrauma, where MSCs adopt pro-inflammatory phenotypes and demonstrate impaired homing. Clinical applications of MSC-based therapies are discussed, including bone marrow aspirate concentrates and tissue-engineered constructs, alongside their potential for systemic immunomodulation in trauma patients. Throughout, we distinguish endogenous MSC behavior in polytrauma from exogenous MSC-based therapies, and we separate various MSC-based therapies as biologically and translationally distinct concepts. Finally, we outline critical knowledge gaps and propose future research directions, including development of representative polytrauma models, optimization of MSC delivery methods, and exploration of MSC-derived extracellular vesicles as therapeutic alternatives to improve outcomes in polytraumatized patients.
Related
- Angiogenic Potential of Small Extracellular Vesicles Produced by Stimulated Mesenchymal Stromal Cells Under Hypoxic Conditions
- Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles for Tendon Regeneration: Insights into Inflammatory and Angiogenesis Modulation
- Long non-coding RNAs in monocyte/macrophage-mediated immune dysregulation and organ injury in sepsis: mechanistic insights and therapeutic potential.
- Tissue Transglutaminase (TG2) as a Candidate Biomarker and Potential Therapeutic Target in Endometriosis: Functional Evidence from shRNA-Mediated Downregulation of TG2 in Endometrial Mesenchymal Stem Cells.
- Therapeutic Potential of Bone Marrow-Derived Mesenchymal Stem Cells in A Letrozole-Induced Rat Model of Polycystic Ovary Syndrome
BibTeX
@article{black2026mesenchymal,
title = {{Mesenchymal stromal cells in polytrauma: from immune dysregulation to therapeutic potential.}},
author = {Charles S Black and Milen Kumar and Renato Miguel Reyes and J Kent Leach and Mark A Lee and Håvard Jostein Haugen and Thaqif El Khassawna and Maryam Rahmati and Augustine Mark Saiz},
journal = {Frontiers in bioengineering and biotechnology},
year = {2026},
month = oct,
doi = {10.3389/fbioe.2026.1892227},
url = {https://europepmc.org/article/MED/42903473},
note = {CC BY},
}
RIS
TY - JOUR
TI - Mesenchymal stromal cells in polytrauma: from immune dysregulation to therapeutic potential.
AU - Charles S Black
AU - Milen Kumar
AU - Renato Miguel Reyes
AU - J Kent Leach
AU - Mark A Lee
AU - Håvard Jostein Haugen
AU - Thaqif El Khassawna
AU - Maryam Rahmati
AU - Augustine Mark Saiz
PY - 2026
DA - 2026/10/06
JO - Frontiers in bioengineering and biotechnology
DO - 10.3389/fbioe.2026.1892227
UR - https://europepmc.org/article/MED/42903473
AB - Polytrauma, defined as life-threatening injuries to multiple organ systems with an Injury Severity Score greater than 16, presents significant challenges for fracture healing, with nonunion rates substantially higher than in isolated fractures. The systemic inflammatory response syndrome (SIRS) and subsequent immune dysregulation characteristic of polytrauma create a hostile microenvironment that impairs normal bone regeneration. Mesenchymal stromal cells (MSCs; also termed mesenchymal stem/stromal cells) play critical roles in fracture healing through immunomodulation, osteogenic differentiation, and promotion of angiogenesis. However, emerging evidence suggests that MSC-mediated processes may be compromised in polytrauma settings. Importantly, direct evidence for endogenous MSC dysfunction in human polytrauma remains limited: much of the current understanding is inferred from isolated-fracture models, in vitro inflammatory-stimulation studies, and animal polytrauma systems rather than from controlled human trauma data. This review examines the mechanisms by which polytrauma is associated with disruption of MSC function, including altered macrophage polarization, excessive neutrophil activation, reduced regulatory T cell populations, and complement-mediated MSC injury. We synthesize the current understanding of MSC immunomodulatory effects in normal fracture healing and contrast this with their dysfunction in polytrauma, where MSCs adopt pro-inflammatory phenotypes and demonstrate impaired homing. Clinical applications of MSC-based therapies are discussed, including bone marrow aspirate concentrates and tissue-engineered constructs, alongside their potential for systemic immunomodulation in trauma patients. Throughout, we distinguish endogenous MSC behavior in polytrauma from exogenous MSC-based therapies, and we separate various MSC-based therapies as biologically and translationally distinct concepts. Finally, we outline critical knowledge gaps and propose future research directions, including development of representative polytrauma models, optimization of MSC delivery methods, and exploration of MSC-derived extracellular vesicles as therapeutic alternatives to improve outcomes in polytraumatized patients.
SN - 2296-4185
ER -